ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,213.49
0.51%
Dow Jones
38,707.70
1.26%
Gold vs US Dollar
2,301.015
-0.11%
Brent Oil
83.035
-0.71%
Bitcoin
61,859.84
4.63%
Pepperstone
Advertisement
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Hutchmed (china) Limited (HCM)

  7. Hutchmed (china) Limited (HCM) News

Hutchmed (china) (HCM)

Hutchmed (china) Limited
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:HCM
DateTimeSourceHeadlineSymbolCompany
26/04/202416:09Alliance NewsAlliance NewsHutchmed notes CHMP's positive opinion for fruiquintinib approvalLSE:HCMHutchmed (china) Limited
26/04/202413:30RNS Regulatory NewsHutchmed (China) Limited Positive CHMP Opinion for FruquintinibLSE:HCMHutchmed (china) Limited
22/04/202409:30RNS Regulatory NewsHutchmed (China) Limited Vesting of Awards Under the LTIPLSE:HCMHutchmed (china) Limited
08/04/202409:30RNS Regulatory NewsHutchmed (China) Limited 2023 Annual Report and Notice of AGMLSE:HCMHutchmed (china) Limited
05/04/202409:30RNS Non-RegulatoryHutchmed (China) Limited Data to be Presented at AACR Congress 2024LSE:HCMHutchmed (china) Limited
02/04/202410:32Alliance NewsAlliance NewsHutchmed endometrial cancer treatment application accepted for reviewLSE:HCMHutchmed (china) Limited
02/04/202407:00RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED and Innovent Announce NDA AcceptanceLSE:HCMHutchmed (china) Limited
28/03/202411:08Alliance NewsAlliance NewsHutchmed lung cancer treatment accepted for review in ChinaLSE:HCMHutchmed (china) Limited
28/03/202407:00RNS Non-RegulatoryHutchmed (China) Limited Savolitinib sNDA Accepted in ChinaLSE:HCMHutchmed (china) Limited
22/03/202410:09Alliance NewsAlliance NewsHutchmed begins registration stage for sovleplenib phase 2/3 trialLSE:HCMHutchmed (china) Limited
22/03/202407:16Alliance NewsAlliance News*CORRECT: Hutchmed China initiates registration for phase 3 trials of sovleplenibLSE:HCMHutchmed (china) Limited
22/03/202407:00RNS Non-RegulatoryHutchmed (China) Limited Initiation of Registration Stage of P2/3 TrialLSE:HCMHutchmed (china) Limited
14/03/202409:00RNS Regulatory NewsHutchmed (China) Limited LTIP and Share Option SchemeLSE:HCMHutchmed (china) Limited
05/03/202408:30RNS Regulatory NewsHutchmed (China) Limited Vesting of awards under the LTIPLSE:HCMHutchmed (china) Limited
28/02/202417:31Alliance NewsAlliance NewsEARNINGS: Hutchmed revenue surges, Craven House's loss widensLSE:HCMHutchmed (china) Limited
28/02/202412:45RNS Non-RegulatoryHutchmed (China) Limited Publication of Form 20-FLSE:HCMHutchmed (china) Limited
28/02/202411:30RNS Regulatory NewsHutchmed (China) Limited 2023 Full Year Results and Business UpdatesLSE:HCMHutchmed (china) Limited
07/02/202409:50Alliance NewsAlliance NewsHutchmed hails fruquintinib trial results for gastric cancer treatmentLSE:HCMHutchmed (china) Limited
07/02/202407:00RNS Non-RegulatoryHutchmed (China) Limited Presentation of Phase III Data on FruquintinibLSE:HCMHutchmed (china) Limited
02/02/202409:52Alliance NewsAlliance NewsHutchmed says Inmagene exercises option to licence drug candidatesLSE:HCMHutchmed (china) Limited
02/02/202408:37RNS Non-RegulatoryHutchmed (China) Limited Inmagene Exercises Option for Two Drug CandidatesLSE:HCMHutchmed (china) Limited
01/02/202408:30RNS Regulatory NewsHutchmed (China) Limited HUTCHMED to Announce 2023 Final ResultsLSE:HCMHutchmed (china) Limited
30/01/202409:20Alliance NewsAlliance NewsHutchmed celebrates cancer drug approval in hometown of Hong KongLSE:HCMHutchmed (china) Limited
30/01/202407:12RNS Non-RegulatoryHutchmed (China) Limited HUTCHMED Receives Marketing Approval in Hong KongLSE:HCMHutchmed (china) Limited
11/01/202410:17Alliance NewsAlliance NewsTOP NEWS: Hutchmed Sovleplenib accepted for review by China drug bureauLSE:HCMHutchmed (china) Limited
11/01/202407:00RNS Non-RegulatoryHutchmed (China) Limited Sovleplenib NDA Granted Priority Review in ChinaLSE:HCMHutchmed (china) Limited
29/12/202308:30UK RegulatoryHutchmed (China) Limited Blocklisting Six Monthly ReturnLSE:HCMHutchmed (china) Limited
29/12/202308:30UK RegulatoryHutchmed (China) Limited Total Voting RightsLSE:HCMHutchmed (china) Limited
21/12/202311:36Alliance NewsAlliance NewsIN BRIEF: Hutchmed China renews deals with "substantial" shareholdersLSE:HCMHutchmed (china) Limited
21/12/202310:00UK RegulatoryHutchmed (China) Limited Overseas Regulatory AnnouncementLSE:HCMHutchmed (china) Limited
 Showing the most relevant articles for your search:LSE:HCM

Your Recent History

LSE
TERN
Tern
LSE
AGL
Angle
LSE
POS
Plexus
LSE
BIRD
Blackbird
LSE
AAZ
Anglo Asian Mining
LSE
SCE
Surface Transforms
LSE
PHNX
Phoenix
LSE
BT.A
Bt
LSE
SCLP
Scancell
LSE
AAU
Ariana Resources
LSE
IES
Invinity Energy Systems
LSE
ZPHR
Zephyr Energy
LSE
DELT
Deltic Energy
LSE
VAST
Vast Resources
LSE
LLOY
Lloyds Banking
LSE
GOLD
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved